The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...
Glioblastoma (GBM), the most common malignant brain tumor, remains difficult to treat because cancer stem cells (CSCs) drive resistance and recurrence. Although the Bruton tyrosine kinase (BTK) ...
ORLANDO, Fla. — Patients who took pirtobrutinib (Jaypirca) had a similar overall response rate to those who took ibrutinib. This was the case for those with both treatment-naive and ...
When you’re a fitness newbie, there are a lot of terms to learn—rep, set, volume, AMRAP, EMOM—I can’t blame you if you’re wondering what it all means. When it comes to the names of types of training, ...
Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...
The manuscript reports on an important comparison of a range of approved clinical inhibitors for BTK used for the treatment of chronic lymphocytic leukemia (CLL). The authors provide solid evidence ...
Bruton tyrosine kinase (BTK) inhibitors are commonly used in the treatment of hematological cancers. However, approximately 67% of patients with relapsed chronic lymphocytic leukemia (CLL) develop ...
A new study identifies potential immune profile differences in patients with chronic lymphocytic leukemia (CLL) that may lead to resistance after ibrutinib therapy. Researchers analyzed peripheral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback